In vivo and in vitro treatment with the synthetic cannabinoid CP55,940 decreases the in vitro migration of macrophages in the rat: Involvement of both CB1 and CB2 receptors

Journal of Neuroimmunology

Volumn 109, Issue 2, 2000, Pages 155-163

  Sacerdote, Paola ^a   Massi, Paola ^a   Panerai, Alberto E ^a   Parolaro, Daniela ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cannabinoid; CB1 receptor; CB2 receptor; Chemotaxis; CP55,940; Inflammation; Macrophage

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID; CANNABINOID B1 RECEPTOR; CANNABINOID B2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; FORMYLMETHIONYLLEUCYLPHENYLALANINE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHEMOTAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; IMMUNE DEFICIENCY; MACROPHAGE MIGRATION; MALE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; RAT;

ANIMAL; BORNANES; CANNABINOIDS; CELL MOVEMENT; CELLS, CULTURED; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNOSUPPRESSIVE AGENTS; IN VITRO; MACROPHAGES, PERITONEAL; MALE; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DRUG;

EID: 0034703186     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(00)00307-6     Document Type: Article

References (28)

1. Bianchi M., Sacerdote P., Rossoni G., Panerai A.E. Effects of tramadol on experimental inflammation. Fundam. Clin. Pharmacol. 13:1999;220-225.
2. Burstein S., Budrow J., Debatis M., Hunter S.A., Subramanian A. Phospholipase participation in cannabinoid-induced release of free arachidonic acid. Biochem. Pharmacol. 48:1994;1253-1264.
3. Cabral G.A., Dove-Pettit D.A. Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. J. Neuroimmunol. 83:1998;116-123.
4. Compton D.R., Aceto M.D., Lowe J., Martin B.R. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of D9-tetrahydrocannabinol-induced responses and apparent agonistic activity. J. Pharmacol. Exp. Ther. 277:1996;586-594.
5. Daaka Y., Friedman H., Klein T.W. Cannabinoid receptor proteins are increased in Jurkat, human T-cell lines after mitogen stimulation. J. Pharmac. Exp. Ther. 276:1996;776-783.
6. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., et al. Expression of central and peripheral cannabinoid receptor in human tissue and leukocyte subpopulation. Eur. J. Biochem. 232:1995;54-61.
7. Grimm M.C., Ben-Baruch A., Taub D.D., Howard O.M.Z., Resau H.J., Wang J.M., et al. Opiates transdeactivate chemokine receptors: δ and μ opiate-receptor-mediated heterologous desensitization. J. Exp. Med. 188:1998;317-325.
8. Hunter S.A., Burstein S.H. Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis. Life Sci. 60:1997;1563-1573.
9. Kaminsky N.E. Regulation of the cAMP cascade, gene expression and immune function by cannabinoid receptors. J. Neuroimmunol. 83:1998;124-132.
10. Kaminsky N.E., Abood M.E., Kessler F.K., Martin B.R., Schatz A.R. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol. Pharmac. 42:1992;736-742.
11. Klein T.W., Newton C., Zhu W., Daaka Y., Friedman H. Delta 9-tetrahydrocannabinol, cytokines, and immunity to Legionella pneumophila. Proc. Soc. Exp. Bio. Med. 209:1995;205-212.
12. Klein W.K., Newton C., Friedman H. Cannabinoid receptors and immunity. Immunol. Today. 19:1998;373-381.
13. Landsman R.S., Burkey T.H., Consroe P., Roeske W.R., Yamamura H.L. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur. J. Pharmacol. 334:1997;R1-R2.
14. Massi P., Patrini G., Rubino T., Fuzio D., Parolaro D. Changes in rat spleen cannabinoids receptors after chronic CP55,940: an autoradiographic study. Pharmacol. Biochem. Behav. 56:1997;821-827.
15. Massi P., Sacerdote P., Ponti W., Fuzio D., Manfredi B., Vigano D., Rubino T., Bardotti M., Parolaro D. Immune function alterations in mice tolerant to tetraidrocannabinol: functional and biochemical parameters. J. Neuroimmunol. 92:1998;60-66.
16. Massi P., Fuzio D., Vigano D., Sacerdote P., Parolaro D. Relative involvement of cannabinoid CB1 and CB2 receptors in the Δ9-tetrahydrocannabinol-induced inhibition of natural killer activity. Eur. J. Pharmacol. 387:2000;343-347.
17. Patrini G., Sacerdote P., Fuzio D., Manfredi B., Parolaro D. Regulation of immune functions in rat splenocytes after acute and chronic in vivo treatment with CP55,940, a synthetic cannabinoid compound. J. Neuroimmunol. 80:1997;143-148.
18. Pertwee R.G. Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 68:1999;635-664.
19. Portier M., Rinaldi-Carmona M., Pecceu F., Combes T., Poinot-Chazel C., Calandra B., et al. SR144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. J. Pharmacol. Exp. Ther. 288:1999;582-589.
20. Prossnitz E.R., Ye R.D. The N-formyl peptide receptor: a model for the study of chemoattractant receptor structure and function. Pharmacol. Ther. 74:1997;73-102.
21. Rinaldi Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., et al. SR141716A a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
22. Rinaldi Carmona M., Barth F., Millan J., Derocq J.M., Casellas P., Chongy C., et al. SR144528 the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284:1998;644-650.
23. Sacerdote P., Bianchi M., Panerai A.E. In vivo and in vitro clomipramine treatment decreases the migration of macrophages in the rat. Eur. J. Pharmacol. 319:1997;287-290.
24. Sacerdote P., Panerai A.E. Analysis of the beta-endorphin structure-related activity on human monocyte chemotaxis: importance of the N- and C-terminal. Peptides. 10:1989;565-569.
25. Schiffmann E. Leukocyte chemotaxis. Annu. Rev. Physiol. 44:1982;553-573.
26. Vasquez C., Lewis D.L. The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors. J. Neurosci. 19:1999;2271-2280.
27. Wahl S.M. Inflammation and wound healing. Oppenheim J., Rosenstreich D., Potter M. Cellular Functions in Immunity and Inflammation. 1981;55-85 Elsevier/North Holland, New York, NY.
28. Wenzel-Seifert K., Hurt C.M., Seifert R. High constitutive activity of the human formyl peptide receptor. J. Biol. Chem. 273:1998;24181-24189.